0LKB Stock Overview
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.47 |
| 52 Week High | US$6.84 |
| 52 Week Low | US$3.30 |
| Beta | 0.78 |
| 1 Month Change | 14.82% |
| 3 Month Change | 18.65% |
| 1 Year Change | -27.26% |
| 3 Year Change | -73.22% |
| 5 Year Change | -71.61% |
| Change since IPO | -74.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0LKB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -14.3% | -0.4% | 2.2% |
| 1Y | -27.3% | -29.1% | 0.9% |
Return vs Industry: 0LKB exceeded the UK Biotechs industry which returned -29.1% over the past year.
Return vs Market: 0LKB underperformed the UK Market which returned 0.9% over the past year.
Price Volatility
| 0LKB volatility | |
|---|---|
| 0LKB Average Weekly Movement | 15.7% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0LKB has not had significant price volatility in the past 3 months.
Volatility Over Time: 0LKB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 203 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.
Vanda Pharmaceuticals Inc. Fundamentals Summary
| 0LKB fundamental statistics | |
|---|---|
| Market cap | US$257.77m |
| Earnings (TTM) | US$2.51m |
| Revenue (TTM) | US$192.64m |
102.7x
P/E Ratio1.3x
P/S RatioIs 0LKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0LKB income statement (TTM) | |
|---|---|
| Revenue | US$192.64m |
| Cost of Revenue | US$14.80m |
| Gross Profit | US$177.84m |
| Other Expenses | US$175.34m |
| Earnings | US$2.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.044 |
| Gross Margin | 92.32% |
| Net Profit Margin | 1.30% |
| Debt/Equity Ratio | 0% |
How did 0LKB perform over the long term?
See historical performance and comparison